In addition, TNBC tumors often have CCND1 amplifications, and CCND1 overexpression reduces global transcription activity and increases RNA polymerase II pausing, thereby sensitizing lymphoid tumor cells to inhibition of the TM via CDK7 or CDK9 [146]. The gene discussed is CCND1; the disease is lymphoid neoplasm.